SequelSEC

Mosaic ImmunoEngineering Inc. CPMV

Biological Products, (No Diagnostic Substances) · CIK 0000836564 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$156.72K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Mosaic ImmunoEngineering Inc. (CPMV) reported net income of -$177.50K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Mosaic ImmunoEngineering Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Mosaic ImmunoEngineering Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$156.72K-$154.80K-$148.13K-$144.36K-$148.85K-$174.77K-$150.16K-$186.43K-$274.30K-$268.77K
Net income-$177.50K-$175.35K-$169.14K-$165.36K-$172.03K-$181.32K-$153.04K-$186.73K-$293.72K-$288.49K
Research & development$15.61K$15.88K$16.13K$16.04K$16.01K$15.80K$16.25K$39.60K$60.71K$67.31K
Weighted-average diluted sharesshares 7.24Mshares 7.24MUnavailableshares 7.24Mshares 7.24Mshares 7.24MUnavailableshares 7.24Mshares 7.24Mshares 7.24M
Pretax income-$177.50K-$175.35K-$169.14K-$165.36K-$169.63K-$181.32K-$150.64K-$186.73K-$293.72K-$288.49K
Income tax expense$0$0$0$0$2.40K$0$2.40K$0$0$0
Diluted EPS$-0.02$-0.02Unavailable$-0.02$-0.02$-0.03Unavailable$-0.03$-0.04$-0.04
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$141.11K$138.92K$132.00K$128.32K$132.85K$158.97K$133.91K$146.83K$213.60K$201.46K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Mosaic ImmunoEngineering Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$26$72$3.62K$31.76K$53.58K$85.93K$115.02K$5.74K$3.73K$65.04K
Total assets$3.28K$9.83K$19.88K$55.30K$57.70K$97.78K$141.61K$39.95K$12.28K$78.95K
Current assets$3.28K$9.83K$19.88K$55.30K$57.70K$97.78K$141.61K$39.95K$12.28K$78.95K
Total liabilities$7.83M$7.66M$7.50M$7.36M$7.20M$7.07M$6.93M$6.68M$6.46M$6.23M
Current liabilities$6.33M$6.18M$6.03M$5.91M$5.77M$5.66M$5.54M$5.30M$5.11M$4.90M
Total equity incl. NCI-$7.83M-$7.65M-$7.48M-$7.31M-$7.14M-$6.97M-$6.79M-$6.64M-$6.45M-$6.15M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$183.23K$167.06K$132.78K$133.76K$133.81K$138.13K$134.86K$143.62K$125.04K$129.45K

Cash flow

Mosaic ImmunoEngineering Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$46-$3.55K-$28.14K-$21.82K-$32.35K-$29.09K-$20.72K-$13.00K-$116.30K-$91.14K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0$0
Financing cash flowUnavailableUnavailable$0$0UnavailableUnavailable$130.00K$15.00KUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$0$0$0$0$0$0$0$0$0$4.87K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Mosaic ImmunoEngineering Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.00x0.00x0.00x0.01x0.01x0.02x0.03x0.01x0.00x0.02x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CPMV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.